Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying its DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease, renal disease and CNS disorders, among others. In 2009, Concert's first patents were granted by the USPTO and the Company announced a $1 billion strategic partnership with GlaxoSmithKline to develop and commercialize deuterium-containing drugs, including a protease inhibitor for the treatment of HIV.

Doug Cole is on the Board of Directors.